Louisiana Restaurants to Disclose Use of Foreign Shrimp and Crawfish
May 29, 2019 13:28 ET
|
American Shrimp Processors Association
BILOXI, Miss., May 29, 2019 (GLOBE NEWSWIRE) -- In a move to protect Louisiana consumers from “the health risks associated chemicals and residues in imported seafood,” the Louisiana Senate...
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
March 18, 2019 11:00 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN)...
Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
March 14, 2019 07:00 ET
|
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ’Company’) Summit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at...
BioAegis Therapeutics Expands Phase 1b/2a Community-Acquired Pneumonia Study to the Republic of Georgia —Successfully Completes Second of Four Dosing Cohorts
February 07, 2019 09:17 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study
February 01, 2019 10:53 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of...
Fedora Pharmaceuticals and Meiji Seika Pharma Sign Basic Agreement to Establish NacuGen Therapeutics Inc., a Joint Venture to Develop and Commercialize Nacubactam for Bacterial Infections
January 07, 2019 09:00 ET
|
Nacugen Therapeutics, Inc.
EDMONTON, Alberta and Tokyo , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. (headquarters: Edmonton, Alberta, Canada; Chief Executive Officer: Christopher G. Micetich, hereinafter...
New Genomic Technology Advances Fight Against Global Health Threat of Antibiotic Resistance
December 06, 2018 09:14 ET
|
Phase Genomics
SEATTLE, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Phase Genomics, the leader in proximity-ligation genome assembly technology released an antimicrobial resistance (AMR) study led by researchers from the...
BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round
September 18, 2018 08:52 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
HP Delivers Innovations to Public Health with New CDC Pilot Program
August 27, 2018 11:01 ET
|
HP Inc.
News highlights CDC launches HP pilot program with the purchase of HP BioPrinters for four regional labs in New York, Minnesota, Tennessee, and Wisconsin.HP BioPrinters, with inkjet printing...
Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
June 11, 2018 07:00 ET
|
Summit Therapeutics plc
Highlights the Power of the Discuva Platform to Identify Novel Antibiotic Targets OXFORD, United Kingdom and CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...